Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma

Paul W. Ladenson, Lewis E. Braverman, Ernest L. Mazzaferri, Françoise Brucker-Davis, David S. Cooper, Jeffrey R. Garber, Fredric E. Wondisford, Terry F. Davies, Leslie J. Degroot, Gilbert H. Daniels, Douglas S. Ross, Bruce D. Weintraub, Ian D. Hay, Silvina Levis, James C. Reynolds, Jacob Robbins, David V. Becker, Ralph R. Cavalieri, Harry R. Maxon, Kevin McEllinRichard Moscicki

Research output: Contribution to journalArticle

367 Scopus citations

Abstract

Background: To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of thyroid hormone therapy may be required to raise serum thyrotropin concentrations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed. However, withdrawal of thyroid hormone therapy causes hypothyroidism. Administration of recombinant human thyrotropin stimulates thyroid tissue without requiring the discontinuation of thyroid hormone therapy. Methods: One hundred twenty-seven patients with thyroid cancer underwent whole-body radioiodine scanning by two techniques: first after receiving two doses of thyrotropin while thyroid hormone therapy was continued, and second after the withdrawal of thyroid hormone therapy. The scans were evaluated by reviewers unaware of the conditions of scanning. The serum thyroglobulin concentrations and the prevalence of symptoms of hypothyroidism and mood disorders were also determined. Results: Sixty-two of the 127 patients had positive whole-body radioiodine scans by one or both techniques. The scans obtained after stimulation with thyrotropin were equivalent to the scans obtained after withdrawal of thyroid hormone in 41 of these patients (66 percent), superior in 3 (5 percent), and inferior in 18 (29 percent). When the 65 patients with concordant negative scans were included, the two scans were equivalent in 106 patients (83 percent). Eight patients (13 percent of those with at least one positive scan) were treated with radioiodine on the basis of superior scans done after withdrawal of thyroid hormone. Serum thyroglobulin concentrations increased in 15 of 35 tested patients: 14 after withdrawal of thyroid hormone and 13 after administration of thyrotropin. Patients had more symptoms of hypothyroidism (P<0.001) and dysphoric mood states (P<0.001) after withdrawal of thyroid hormone than after administration of thyrotropin. Conclusions: Thyrotropin stimulates radioiodine uptake for scanning in patients with thyroid cancer, but the sensitivity of scanning after the administration of thyrotropin is less than that after the withdrawal of thyroid hormone. Thyrotropin scanning is associated with fewer symptoms and dysphoric mood states.

Original languageEnglish (US)
Pages (from-to)888-896
Number of pages9
JournalNew England Journal of Medicine
Volume337
Issue number13
DOIs
StatePublished - Sep 25 1997

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ladenson, P. W., Braverman, L. E., Mazzaferri, E. L., Brucker-Davis, F., Cooper, D. S., Garber, J. R., Wondisford, F. E., Davies, T. F., Degroot, L. J., Daniels, G. H., Ross, D. S., Weintraub, B. D., Hay, I. D., Levis, S., Reynolds, J. C., Robbins, J., Becker, D. V., Cavalieri, R. R., Maxon, H. R., ... Moscicki, R. (1997). Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine, 337(13), 888-896. https://doi.org/10.1056/NEJM199709253371304